Delving into the Latest Updates on Empagliflozin/Linagliptin/Metformin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

EmpaLinaMet XR, Empagliflozin/Linagliptin/Metformin, Empagliflozin/metformin/linagliptin

+ [5]

Target

DPP-4 x PRKAB1 x SGLT2

Action

inhibitors, activators

Mechanism

DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Boehringer Ingelheim Pharmaceuticals, Inc.

Inactive Organization

Boehringer Ingelheim GmbH

Drug Highest PhaseApproved

First Approval Date

United States (27 Jan 2020),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H27ClO7

InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N

CAS Registry864070-44-0

View All Structures (3)

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Start Date01 Apr 2025

Sponsor / Collaborator

Nabiqasim Industries (Pvt) Ltd

NCT03629054

/ CompletedPhase 1

Bioequivalence of a Low Strength Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)

The primary objective of this trial is to establish the bioequivalence of two empagliflozin/linagliptin/metformin extended release (XR) fixed dose combination (FDC) tablets (Test, T) compared with the same doses of the individual components given in separate tablets (Reference, R) when administered together after a high-fat, high-calorie meal.
The assessment of safety and tolerability will be the secondary objective of this trial.

Start Date27 Aug 2018

Sponsor / Collaborator

Boehringer Ingelheim GmbH

[+1]

NCT03259490

/ CompletedPhase 1

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)

To establish the bioequivalence of one fixed dose combination (FDC) tablet of empagliflozin/linagliptin/metformin extended release (XR) versus the free combination of empagliflozin tablet, linagliptin tablet, and metformin XR tablets administered as a single dose under fed conditions

Start Date31 Aug 2017

Sponsor / Collaborator

Boehringer Ingelheim GmbH

[+1]

100 Clinical Results associated with Empagliflozin/Linagliptin/Metformin Hydrochloride

Login to view more data

100 Translational Medicine associated with Empagliflozin/Linagliptin/Metformin Hydrochloride

Login to view more data

100 Patents (Medical) associated with Empagliflozin/Linagliptin/Metformin Hydrochloride

Login to view more data

1

Literatures (Medical) associated with Empagliflozin/Linagliptin/Metformin Hydrochloride

01 Jun 2020·The Medical letter on drugs and therapeuticsQ4 · MEDICINE

In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.

Q4 · MEDICINE

Article

100 Deals associated with Empagliflozin/Linagliptin/Metformin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10BD	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	27 Jan 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03629054 (CTgov)	Phase 1	-	30	Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination) (Test Treatment (T))	jbsjfggdyd(dhthbfwxfy) = yqtambdyfk mcxryskjeo (jjtpbzfpuc, rqsbpqkkgi - dxqkfqfvsz) View more	-	21 Feb 2020
				Linagliptin+Metformin HCl+Empagliflozin (Reference Treatment (R))	jbsjfggdyd(dhthbfwxfy) = wtmezwqibj mcxryskjeo (jjtpbzfpuc, fwkccnxpxu - ioubadgdzj) View more